Xania Darden, COSMETOLOGIST Dermatology Medicare: Not Enrolled in Medicare Practice Location: 23331 El Toro Rd, Suite 114, Lake Forest, CA 92630 Phone: 949-215-0994 |
Azin Meshkinpour, M.D., M.P.H. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 24432 Muirlands Blvd, Suite 219, Lake Forest, CA 92630 Phone: 949-770-8115 Fax: 949-770-2017 |
Ira Bell, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 23832 Rockfield Blvd, Ste 210, Lake Forest, CA 92630 Phone: 949-770-8115 Fax: 949-770-2017 |
Karen Benik, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 23832 Rockfield Blvd Ste 210, Lake Forest, CA 92630 Phone: 949-770-8115 Fax: 949-770-2017 |
Kim Thu Tang, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 23832 Rockfield Blvd Ste 210, Lake Forest, CA 92630 Phone: 949-770-8115 Fax: 949-770-2017 |
Sam Van Truong, M.D. Dermatology - MOHS-Micrographic Surgery Medicare: Accepting Medicare Assignments Practice Location: 23832 Rockfield Blvd Ste 220, Lake Forest, CA 92630 Phone: 949-770-8115 |
News Archive
Pacific Edge Limited, a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announces today the commercial launch of the third product in the Company's Cxbladder family of products, Cxbladder Monitor, in the United States.
Imagine if a naturally occurring chemical in your body could help make you feel more calm and relaxed ? but it would only work during the long days of summer.
Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan.
Students who received eyeglasses through a school-based program scored higher on reading and math tests, Johns Hopkins researchers from the Wilmer Eye Institute and School of Education found in the largest clinical study of the impact of glasses on education ever conducted in the United States.
ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).
› Verified 3 days ago